9月26日，英科医疗盘中上涨2.01%，截至10:22，报37.54元/股，成交1.71亿元，换手率1.00%，总市值 245.81亿元。 资金流向方面，主力资金净流出745.45万元，特大单买入412.42万元，占比2.41%，卖出658.84万元，占 比3.86%；大单买入2395.34万元，占比14.02%，卖出2894.37万元，占比16.94%。 英科医疗今年以来股价涨49.08%，近5个交易日涨5.27%，近20日涨2.21%，近60日涨46.64%。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 英科医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医用耗材、智慧医疗、 抗原检测、医疗器械、跨境电商等。 截至6月30日，英科医疗股东户数6.00万，较上期减少2.96%；人均流通股7825股， ...

英科医疗今年以来股价涨46.94%，近5个交易日涨3.99%，近20日跌1.73%，近60日涨45.15%。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 9月25日，英科医疗盘中下跌2.01%，截至13:50，报37.00元/股，成交4.68亿元，换手率2.67%，总市值 242.27亿元。 资金流向方面，主力资金净流出1567.62万元，特大单买入1279.07万元，占比2.73%，卖出2541.32万 元，占比5.43%；大单买入8113.51万元，占比17.34%，卖出8418.87万元，占比17.99%。 截至6月30日，英科医疗股东户数6.00万，较上期减少2.96%；人均流通股7825股，较上期增加3.07%。 2025年1月-6月，英科医疗实现营业收入49.13亿元，同比增长8.90%；归母净利润7.10亿 ...

Core Viewpoint - Sanyou Medical's stock price has shown fluctuations, with a year-to-date increase of 12.89% and a recent decline of 13.12% over the past 20 days, indicating volatility in the market [1][2]. Company Overview - Sanyou Medical, established on April 19, 2005, and listed on April 9, 2020, specializes in the research, production, and sales of medical orthopedic implants and ultrasonic power equipment and consumables [1]. - The company's revenue composition includes spinal implant consumables (63.80%), active devices and supporting accessories (31.51%), trauma implant consumables (3.53%), and others (1.16%) [1]. Financial Performance - For the first half of 2025, Sanyou Medical reported a revenue of 250 million yuan, representing a year-on-year growth of 17.77% [2]. - The net profit attributable to the parent company reached 36.60 million yuan, showing a significant year-on-year increase of 2083.64% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 12.61% to 7,108, while the average circulating shares per person decreased by 11.20% to 34,954 shares [2]. - Cumulative cash dividends since the A-share listing amount to 113 million yuan, with 39.75 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include notable funds, with Rongtong Health Industry Flexible Allocation Mixed A/B holding 9.98 million shares, a decrease of 1.52 million shares from the previous period [3].

资料显示，重庆山外山血液净化技术股份有限公司位于重庆市两江新区慈济路1号，成立日期2001年3月 26日，上市日期2022年12月26日，公司主营业务涉及血液净化设备的研发、生产和销售。主营业务收入 构成为：血液净化设备66.12%，血液净化耗材23.89%，医疗服务8.31%，其他1.68%。 山外山所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：医用耗材、智慧医疗、小 盘、医疗器械、专精特新等。 截至6月30日，山外山股东户数8150.00，较上期增加2.67%；人均流通股28779股，较上期减少2.60%。 2025年1月-6月，山外山实现营业收入3.57亿元，同比增长28.72%；归母净利润5503.86万元，同比增长 20.28%。 9月24日，山外山盘中上涨2.16%，截至10:56，报14.66元/股，成交2120.38万元，换手率0.63%，总市值 47.10亿元。 资金流向方面，主力资金净流入24.80万元，大单买入77.10万元，占比3.64%，卖出52.31万元，占比 2.47%。 山外山今年以来股价涨32.55%，近5个交易日跌2.66%，近20日跌5.84%，近60日 ...

Company Overview - Crown Bio is located in Huangpu District, Guangzhou, Guangdong Province, and was established on October 22, 1999. The company was listed on July 6, 2011. Its main business involves the research, production, and sales of regenerative medical materials and regenerative medical implants, as well as research and clinical applications of cell therapy technology and immune cell storage [1][2]. Financial Performance - For the first half of 2025, Crown Bio achieved operating revenue of 201 million yuan, representing a year-on-year growth of 5.89%. The net profit attributable to the parent company was 20.40 million yuan, an increase of 1.27% year-on-year [2]. - Since its A-share listing, Crown Bio has distributed a total of 86.66 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 22, Crown Bio's stock price was 15.37 yuan per share, with a market capitalization of 4.075 billion yuan. The stock has increased by 27.66% year-to-date but has seen a decline of 4.36% over the last five trading days, 11.41% over the last 20 days, and 5.30% over the last 60 days [1]. - The stock experienced a net outflow of 7.55 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Information - As of September 10, the number of shareholders for Crown Bio was 28,200, a decrease of 2.37% from the previous period. The average number of circulating shares per person increased by 2.43% to 9,407 shares [2]. Business Segments - The revenue composition of Crown Bio is as follows: medical devices account for 73.28%, pharmaceuticals for 15.21%, and leasing and other services for 11.51% [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including medical consumables, small-cap stocks, medical beauty, and biomedicine [2].

Core Viewpoint - Sanyou Medical has shown a mixed performance in stock price and financial metrics, with a notable increase in revenue and net profit year-on-year, indicating potential growth in the medical device sector [1][2]. Financial Performance - As of June 30, 2025, Sanyou Medical achieved a revenue of 250 million yuan, representing a year-on-year growth of 17.77% [2]. - The net profit attributable to shareholders reached 36.60 million yuan, marking a significant year-on-year increase of 2083.64% [2]. - The company has distributed a total of 113 million yuan in dividends since its A-share listing, with 39.75 million yuan distributed over the past three years [3]. Stock Performance - On September 22, 2023, Sanyou Medical's stock price increased by 2.15%, reaching 19.99 yuan per share, with a total market capitalization of 6.666 billion yuan [1]. - Year-to-date, the stock price has risen by 13.23%, while it has seen a slight decline of 0.05% over the last five trading days and a drop of 11.00% over the last 20 days [1]. - The stock has appreciated by 24.77% over the past 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 12.61% to 7,108, while the average number of circulating shares per person decreased by 11.20% to 34,954 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease of 1.5154 million shares held by Rongtong Health Industry Flexible Allocation Mixed A/B and an increase of 0.1646 million shares held by Southern Medicine Health Flexible Allocation Mixed A [3]. Business Overview - Sanyou Medical, established on April 19, 2005, and listed on April 9, 2020, specializes in the research, production, and sales of medical orthopedic implants and ultrasonic power devices and consumables [1]. - The company's main revenue sources include spinal implant consumables (63.80%), active devices and supporting accessories (31.51%), trauma implant consumables (3.53%), and others (1.16%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector [1].

Core Viewpoint - Aipeng Medical's stock has experienced significant fluctuations, with a year-to-date increase of 66.92% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 19, Aipeng Medical's stock price was 29.32 CNY per share, with a market capitalization of 3.696 billion CNY [1] - The stock has seen a decline of 5.08% over the last five trading days and 13.92% over the last twenty trading days [2] - Year-to-date, the stock has been on the龙虎榜 (top trading list) six times, with the most recent net buy of 11.9243 million CNY on August 8 [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit of -19.3791 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the A-share listing amount to 113 million CNY, with 16.3862 million CNY distributed over the last three years [3] Group 3: Company Overview - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in pain management and nasal care [2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [2] - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2]

Core Viewpoint - Aipeng Medical's stock price has shown significant volatility, with a year-to-date increase of 77.97% but a recent decline in the last 20 days by 7.71% [2] Group 1: Stock Performance - On September 17, Aipeng Medical's stock fell by 2.04%, trading at 31.26 CNY per share with a total transaction volume of 1.49 billion CNY and a market capitalization of 39.40 billion CNY [1] - The stock has experienced a 3.61% increase over the last five trading days and a 5.50% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 1.59 billion CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the company's A-share listing amount to 113 million CNY, with 16.39 million CNY distributed over the past three years [3] Group 3: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2] - Aipeng Medical has appeared on the trading leaderboard six times this year, with the most recent instance on August 8, where net purchases amounted to 11.92 million CNY [2]

9月15日，澳华内镜盘中下跌2.01%，截至10:01，报48.23元/股，成交1919.84万元，换手率0.29%，总市 值64.95亿元。 资金流向方面，主力资金净流入42.41万元，特大单买入136.65万元，占比7.12%，卖出0.00元，占比 0.00%；大单买入186.18万元，占比9.70%，卖出280.42万元，占比14.61%。 澳华内镜今年以来股价涨20.27%，近5个交易日跌7.52%，近20日跌6.87%，近60日跌0.17%。 资料显示，上海澳华内镜股份有限公司位于上海市闵行区光中路133弄66号，成立日期1994年10月27 日，上市日期2021年11月15日，公司主营业务涉及从事电子内窥镜设备及内窥镜诊疗手术耗材研发、生 产和销售的高新技术企业。主营业务收入构成为：内窥镜设备92.35%，内窥镜诊疗耗材3.71%，内窥镜 维修服务收入3.58%，租赁收入0.35%。 澳华内镜所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：医用耗材、小盘、医疗 器械、养老金概念、专精特新等。 截至6月30日，澳华内镜股东户数3921.00，较上期减少2.51%；人均流通股34344 ...

Core Viewpoint - Zhenghai Biological experienced a stock price increase of 2.18% on September 12, reaching 21.10 CNY per share, with a total market capitalization of 3.798 billion CNY [1] Financial Performance - For the first half of 2025, Zhenghai Biological reported operating revenue of 188 million CNY, a year-on-year decrease of 5.14%, and a net profit attributable to shareholders of 46.49 million CNY, down 45.97% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 617 million CNY, with 334 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Zhenghai Biological was 16,800, a decrease of 0.89% from the previous period, with an average of 10,704 circulating shares per shareholder, an increase of 0.90% [2] - The top ten circulating shareholders include notable funds such as Dongfanghong New Power Mixed A and Dongfanghong JD Big Data Mixed A, with changes in their holdings noted [3] Stock Performance - Year-to-date, Zhenghai Biological's stock price has increased by 1.22%, with a 3.58% rise over the last five trading days, a 4.70% decline over the last 20 days, and an 8.59% increase over the last 60 days [1]